Endocrine Abstracts

Breast cancer cells may present a number of resistance mechanisms to conventional therapy, and therefore new treatments are under evaluation. The histone deacetylase inhibitor (HDI) valproic acid (VPA) is of particular interest, since having been used for a long time in neurological patients its side-effects and tolerability are well known. We have recently demonstrated that VPA is a powerful antiproliferative agent in estrogen-sensitive breast cancer cells. Unfortunately, its...